Trial Profile

A pilot study to assess the influence of drug transporters on brain and organ distribution of erlotinib in humans

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Tariquidar
Indications Bladder cancer; Brain metastases; Ependymoma; Glioblastoma; Gynaecological cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Squamous cell cancer
Focus Pharmacokinetics; Proof of concept

Most Recent Events

13 Jun 2019 Planned End Date changed from 2 Jun 2018 to 2 Jun 2020.
13 Jun 2019 Planned number of patients changed from 77 to 87.
16 Mar 2019 Results (n=22) presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com